MINNEAPOLIS--(BUSINESS WIRE)--Medtronic Inc. (NYSE: MDT), the leader in spinal cord stimulation for more than 25 years, today announced U.S. Food and Drug Administration (FDA) clearance and the global launch of the Multi-Lead Trialing Cable for use in the patient screening test for Medtronic spinal cord stimulation (SCS) therapy. Introduced this month in the United States, Europe and Canada, the streamlined trialing system allows physicians to test a wide array of stimulation settings prior to implanting a neurostimulator to provide long-term pain management.
